Prevalence of Resistant Gram-Negative Bacilli in Bloodstream Infection in Febrile Neutropenia Patients Undergoing Hematopoietic Stem Cell Transplantation

A Single Center Retrospective Cohort Study

Ling Wang, MD, Ying Wang, MD, Xing Fan, MD, Wei Tang, MD, and Jiong Hu, MD

Abstract: Bloodstream infection (BSI) is an important cause of morbidity and mortality in patients undergoing hematopoietic stem cell transplantation (HSCT). To evaluate the causative bacteria and identify risk factors for BSI associated mortality in febrile neutropenia patients undergoing HSCT, we collected the clinical and microbiological data from patients underwent HSCT between 2008 and 2014 and performed a retrospective analysis. Throughout the study period, among 348 episodes of neutropenic fever in patients underwent HSCT, 89 episodes in 85 patients had microbiological defined BSI with a total of 108 isolates. Gram-negative bacteria (GNB) were the most common isolates (76, 70.3%) followed by gram-positive bacteria (GPB, 29, 26.9%) and fungus (3, 2.8%). As to the drug resistance, 26 multiple drug resistance (MDR) isolates were identified. Resistant isolates (n = 23) were more common documented in GNB, mostly Escherichia coli (9/36, 25%) and Klebsiella pneumonia (6/24, 25%). A total of 12 isolated were resistant to carbapenem including 4 Klebsiella pneumonia (4/24, 16.7%), 3 Stenotrophomonas maltophilia, and 1 Pseudomonas aeruginosa and other 4 GNB isolates (Citrobacter freundii, Pseudomonas stutzeri, Acinetobacter baumanii, and Chryseobacterium indologenes). As to the GPB, only 3 resistant isolates were documented including 2 methicillin-resistant isolates (Staphylococcus hominis and Arcanobacterium hemolytis) and 1 vancomycin-resistant Enterococcus faecium. Among these 85 patients with documented BSI, 11 patients died of BSI as primary or associated cause with a BSI-related mortality of 13.1 ± 3.7% and 90-day overall survival after transplantation at 80.0 ± 4.3%. Patients with high-risk disease undergoing allo-HSCT, prolonged neutropenia (>15 days) and infection with carbapenem-resistant GNB were associated with BSI associated mortality in univariate and multivariate analysis. Our report revealed a prevalence of GNB in BSI of neutropenic patients undergoing HSCT. Patients with high-risk diseases with prolonged neutropenia and carbapenem-resistant GNB were independent risk factors for BSI-related mortality.

INTRODUCTION

Neutropenic infection is a major adverse effect of cancer treatment particularly in patients receiving intensive chemotherapy or undergoing hematopoietic stem cell transplantation (HSCT).1,2 Microbiologically documented bloodstream infection (BSI) account for 10% to 30% of the febrile neutropenia (FN) episodes and remains an important cause of morbidity and mortality in HSCT recipients.3–5 The epidemiology data provided the basis for selection of empiric antibiotic therapy for FN. There has been a shift from the predominance of gram-negative bacteria (GNB) to predominance of gram-positive bacteria (GPB) in many centers over the last 2 decades.1,2 At most cancer centers, BSI infections are mainly caused by GNB (about 60%), GPB (about 25%), or fungi (about 10%).3–5

Recently, multiple drug resistance (MDR) pathogens became the most concern worldwide. Extended spectrum beta-lactamase (ESBL) producing Escherichia coli (E. coli) is an increasing issue in the treatment of patients with hematological malignancies. Other MDR bacteria such as Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, and Enterobacter spp. pathogens were also noticed.6 Although the prevalence and pattern of resistance varies among centers; the emergence of resistant bacteria became an even more important problem in China. In the latest released data from national surveillance CHINET study year 2013 based on a total

**Abbreviations:** ALL = acute lymphoblastic leukemia, AML = acute myeloid leukemia, BSI = bloodstream infection, CML = chronic myeloid leukemia, CoNS = coagulase-negative Staphylococcus spp., CR = complete remission, CRE = carbapenem-resistant enterobacteriaceae, E coli = Escherichia coli, EBMT = European Society for Blood and Marrow Transplantation, ESBL = extended spectrum beta-lactamase, FN = febrile neutropenia, FQ = fluoroquinolones, G = (1–3)-β-glucanG, GM = galactomannan, GNB = gram-negative bacteria, GPB = gram-positive bacteria, GvHD = graft versus host disease, HD = Hodgkin’s disease, HSCT = hematopoietic stem cell transplantation, LOH = length of hospital, MDR = multiple drug resistance, MDS = myelodysplasia syndrome, MM = multiple myeloma, MRCSN = methicillin-resistant coagulase-negative Staphylococcus, MRSA = methicillin-resistant Staphylococcus aureus, NHL = non-Hodgkin’s lymphoma, OS = overall survivor, PR = partial remission, SAA = severe aplastic anemia, VOD = veno-occlusion disease, VRE = vancomycin-resistant Enterococcus spp.

**Editor:** Wael Alkhari.

**Received:** July 19, 2015; revised: September 30, 2015; accepted: October 5, 2015.

From the Department of Hematology, Blood and Marrow Transplantation Center, Collaborative Innovation Center of Hematology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (LW, YW, XF, WT, JH).

Correspondence: Jiong Hu, Department of Hematology, Blood and Marrow Transplantation Center, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, 18F/OPD Bldg 197 Rui Jin Road II, Shanghai 200025, China. (e-mail: hujiong@medmail.com.cn).

LW and YW have contributed equally to the manuscript.

The authors have no funding and conflicts of interest to disclose.

**Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.**

This is an open access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0, where it is permissible to download, share and reproduce the work in any medium, provided it is properly cited. The work cannot be changed in any way or used commercially.

**ISSN:** 0025-7974

**DOI:** 10.1097/MD.0000000000001931
of 84,572 clinical isolates, the average prevalence of methicillin-resistant strains in *S. aureus* (MRSA) and coagulase-negative *Staphylococcus* was 45.2% and 73.5%, respectively, while the prevalence of ESBLs producing strains was 54.0% in *E. coli*, 31.8% in *Klebsiella* spp. (*K. pneumoniae* and *K. oxytoca*) and 16.0% in *Proteus mirabilis* on average.7

Since neutropenic BSI and prevalence of drug resistance remained as important clinical issues for patients undergoing HSCT; therefore, we performed a retrospective study to evaluate the local epidemiology of causative bacteria, the prevalence of drug resistance in patients with BSI and the impact of BSI on the treatment outcome in the Blood and Marrow Transplantation Center, Rui Jin Hospital to further optimize the strategies of infection control and antibiotic prophylaxis and treatment in transplantation recipients.

**PATIENTS AND METHODS**

**Study Design and Data Collection**

We conducted a 7-year retrospective study of patients undergoing HSCT at the transplant unit of Department of Hematology at Rui Jin Hospital between January 1, 2008 and December 30, 2014. The aims of this study were: to describe epidemiology and outcome of BSI in neutropenic patients undergoing HSCT; to understand the risk factors of BSI associated mortality. All patients undergoing HSCT with neutropenic (neutrophil count < 0.5 × 10⁹/L) fever with documented BSI were included for analyzed. All microbiology data were provided by the Department of Microbiology and clinical data were gathered from the patient’s clinical records and prospectively kept transplantation database as appropriate. This study was a retrospective evaluation of epidemiology data and therefore did not require ethical approval based on advice of ethics committee, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine.

**Clinical Management**

All patients undergoing transplantation were cared in rooms with laminar airflow until discharge. Before admission to blood and marrow transplantation unit, decontamination using chlorhexidine solution was performed. Routine surveillance cultures and active screening (stool, urine, nose, throat, vagina or penis, and anus) were obtained weekly. In case of colonization of multiple-drug resistance bacteria documented, further contact barrier precautions, environmental cleaning, and surface decontamination were carried out. All patients had an indwelling central venous catheter and received oral levofloxacin and fluconazole prophylaxis until engraftment and until day 100, respectively. Both types of prophylaxis were discontinued in case of need for antibacterial or antifungal therapy.

At the onset of fever (≥38.1°C) or in the presence of any clinical symptom compatible with an infection, 2 sets of blood cultures were drawn from peripheral vein and central catheter. An empirical antibiotic therapy was started, usually with imipenem or cefoperazone sulbactam alone. If patients developed severe mucositis or septic shock, vancomycin was added as combination therapy. Otherwise, vancomycin was added until 48 hr in case of persistent fever. For those patients who remained febrile for 5 days, an empirical antifungal therapy was also started after a chest computed tomography scan and blood test for (1–3)β-D-glucan (G) and/or galactomannan test. Additional blood cultures were then repeated at least every 2 to 3 days or clinically indicated throughout the febrile/infectious episode.

**Definitions**

According to the definitions of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation (EBMT), BSI was defined by the isolation of bacteria or fungi from any blood culture in the context of fever or other clinical signs consistent with infection.5,6 For coagulase-negative *Staphylococci*, at least 2 blood cultures were required to be positive. All episodes of BSI were then subclassified into 4 categories: gram-positive, gram-negative, fungal, and polymicrobial. Polymicrobial BSI was defined as 2 or more pathogens were isolated in a single blood culture or in at least 2 separate blood cultures obtained 96 hr apart.5 For patients who had more than 1 BSI during the study period, the first episode was defined as the primary one, while subsequent episodes were numbered sequentially (2nd, 3rd, etc.). Fever was defined as temperature ≥38.1°C. Neutropenia and severe neutropenia were defined as an absolute granulocyte count <0.5 or <0.1 × 10⁹/L, respectively.

BSI-related death was defined as following: BSI was considered as the primary cause of death if the patient died within 1 week after the last positive blood culture and no other cause (including the underlying disease, persistent neutropenia, other infections and hemorrhage) was identified. BSI was considered an associated cause of death when another cause was also present (uncontrolled underlying disease, persistent neutropenia, and/or graft versus host disease [GvHD]). Death not related or associated with BSI was defined as death considered due to other causes when BSI was cleared at time of death (as indicated by the lack of infection-related symptoms or positive cultures).5

**Pathogen, Identification, and Antimicrobial Susceptibility Testing**

Blood cultures were performed using the BACTEC 9240 (Becton Dickinson, Franklin Lakes, NJ) automated system. Collected isolates were checked by Vitek-2 system and/or phenotypic tests as previously described, and the isolates were recovered to conduct antimicrobial susceptibility testing with the disk diffusion method according to the guidelines of Clinical and Laboratory Standards Institute (CLSI).10,11 As to the drug resistance, the MRSA, vancomycin-resistant *Enterococcus* spp. (VRE), *P. aeruginosa*, *A. baumannii*, and *S. maltophilia* resistant to at least 3 different groups of antibiotics including antipseudomonal penicillins, cephalosporins, carbapenems, aminoglycosides, and fluoro-quinolones were considered as MDR bacteria.12,13

**Statistical Analysis**

The SPSS 19 (Chicago, IL) package program was used for statistical analysis. The distribution of time-to-event endpoints such as overall survivor 90 days after transplantation was estimated using the Kaplan–Meier method. Probability of overall BSI-related mortality was calculated within 90 days after documentation of BSI using reciprocal cumulative incidence estimates. Log-rank test was used for univariate analysis to identify the potential risk factors associated with BSI-related mortality. Multivariate logistic regression analysis was performed to determine risk factors independently associated with BSI-related mortality. P values were reported as 2-sided and <0.05 were statistical significance.

**RESULTS**

Throughout the study period, a total of 348 episodes of neutropenic fever in 273 patients were documented. Out
of 348 episodes, only 89 (22.5%) episodes in 85 patients were found to have documented BSI (85 primary BSI and 4 secondary BSI). The basic characteristics were shown in Table 1. A total of 51 patients with standard-risk disease received transplantation which was defined as acute leukemia in complete remission (CR), lymphoma in CR or partial remission (PR), chronic myeloid leukemia in chronic phase and untreated myelodysplasia syndrome (MDS) or severe aplastic anemia (SAA). A total of 34 patients had high-risk disease (acute leukemia with induction failure or relapse; lymphoma with stable disease or progression disease; chronic myeloid leukemia in accelerated phase or in blast-crisis and MDS/SAA remained transfusion dependence after previous treatment).

A total of 83 patients had documented BSI at median of 5 days (3–9) after transplantation. Among them 2 patients with primary engraft failure developed primary and secondary BSI during the prolonged neutropenia phase after transplantation. Other 2 patients with refractory disease undergoing allo-HSCT developed BSI during the conditioning phase with E coli and K pneumoniae, respectively, and then developed a secondary BSI on days 3 and 5 after allo-HSCT, respectively.

According to the definition of BSI, gram-positive and gram-negative BSI were 22 (25.9%) and 50 (58.8%), respectively. Only 1 fungal BSI (1/85, 1.1%) and 12 polymicrobial BSI were 22 (25.9%) and 50 (58.8%), respectively. More importantly, besides S maltophilia isolates, a total of 9 isolated were resistant to carbapenem with an incidence of 12.3% (9/73) mostly documented in K pneumoniae (4/24, 16.7%) and other Enterobacteriaceae such as P aeruginosa (1/3, 33.3%), P stutzeri (n = 1), A baumannii (n = 1), C freundii (n = 1), and Chryseobacterium indologenes (n = 1) as shown in Table 3. As contrary, few MDR isolates were identified in GPB isolates with only 1 vancomycin-resistant E faecium (3.4%) as shown in Table 4.

All alive patients were followed-up for at least 90 days after transplantation, a total of 17 patients died with a 90-day overall survival after transplantation at 80.0 ± 4.3% as shown in Figure 1. A total of 11 patients died with BSI considered as either primary (n = 4) or associated (n = 7) cause of death leading to a BSI-related mortality rate of 13.1 ± 3.7% (Fig. 1). Among them, 3 patients died within 7 days, 6 patients within 14 days, and 2 patients beyond 15 days after the documentation of BSI. The isolates identified in these patients were GNB in 8 patients including E coli (n = 3, non-MDR isolates), K pneumoniae (n = 2, both MDR/CRE), P aeruginosa (n = 1, MDR/CRE), A baumannii (n = 1, MDR/CRE), and C freundii (n = 1, MDR/CRE). Other 3 patients died of polymicrobial BSI and all had at least 1 documented GNB: E coli (n = 1), P stutzeri (n = 1, MDR/CRE), and S maltophilia (n = 1, MDR/CRE). A total of 6 patients died due to GvHD (n = 2), VOD (n = 1), cranial hemorrhage (n = 2), and relapse disease, respectively.

For risk factors associated with BSI-related mortality, patients with high-risk disease (P = 0.014), undergoing allogeneic HSCT (P = 0.04), BSI with carbapenem-resistant GNB were independently associated with a short overall survival after transplantation.

TABLE 1. Patients’ Characteristics

| Age median, yr (range) | 31 (15–60) |
|------------------------|-----------|
| Male/female gender     | 46/39     |
| Diagnosis              |           |
| AML                    | 22        |
| ALL                    | 16        |
| NHL/HD                 | 13        |
| MM                     | 4         |
| CML                    | 2         |
| SAA                    | 2         |
| MDS                    | 2         |
| Other malignancies     | 4         |
| Disease stages         |           |
| Standard risk          | 51        |
| High risk              | 34        |
| HSCT                   |           |
| Allogeneic             | 63        |
| Autologous             | 22        |
| Duration of neutropenia|           |
| Median (range)         | 17 (5–67) |
| <7 d                   | 8         |
| 8–14 d                 | 50        |
| ≥15 d                  | 26        |

All = acute lymphoblastic leukemia; AML = acute myeloid leukemia; CML = chronic myeloid leukemia; HSCT = hematopoietic stem cell transplant; MDS = myelodysplasia syndrome; MM = multiple myeloma; NHL/HD = non-Hodgkin’s lymphoma/Hodgkin’s disease; SAA = severe aplastic anemia.

Standard risk: acute leukemia in complete remission (CR), NHL/HD in CR or partial remission (PR), CML in chronic phase; MDS or SAA untreated. High-risk: acute leukemia with induction failure or relapse, NHL/HD in stable disease (SD) or in progression (PD), CML in accelerated phase (AP) or in blast-crisis (BC), MDS/SAA transfusion dependence with no response to treatment.

TABLE 2. Annual Distribute of Isolates From BSI Patients

|          | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 |
|----------|------|------|------|------|------|------|------|
| Gram-negative bacteria | 7    | 7    | 12   | 10   | 11   | 10   | 16   |
| Gram-positive bacteria  | 3    | 4    | 3    | 2    | 2    | 5    | 8    |
| Fungal               |      |      |      |      |      |      |      |

BSI = bloodstream infection.
(P < 0.001), and prolonged neutropenia (≥15 days, P < 0.001) were associated with BSI-related mortality in univariate analysis while high-risk disease (P = 0.031, RR 4.4), BSI with carbapenem-resistant GNB (P = 0.04, RR 4.4) and prolonged neutropenia (≥15 days, P = 0.007, RR 16.7) remained significant with multivariate analysis (as shown in Table 5 and Figure 2). When combined these 3 risk factors, it was possible to divide patients into 3 different risk groups for BSI-related mortality: low-risk with 0 to 1 risk factor, intermediate-risk with 2 risk factors, and high-risk with 3 risk factors. Patients in the low-risk group had a BSI-related mortality at 4.5 ± 1.5%, while intermediate- and high-risk patients had significantly increased BSI-related mortality to 41.7 ± 14.2% and 83.3 ± 15.2%, respectively, as shown in Fig. 3.

**TABLE 3.** Isolated Gram-Negative Pathogens and Drug Resistance Between 2008 and 2014

| Pathogens                        | No. of Isolates | Carbopenem Sensitive | CRE  |
|---------------------------------|----------------|----------------------|------|
| Gram-negative bacteria          |                |                      |      |
| Any                             | 76             | 11                   | 12   |
| *Escherichia coli*              | 36             | 9                    | 0    |
| *Klebsiella pneumoniae*         | 24             | 2                    | 4    |
| *Pseudomonas aeruginosa*        | 3              | 0                    | 1    |
| *Stenotrophomonas maltophilia*  | 3              | 0                    | 3    |
| *Pseudomonas stutzeri*          | 1              | 0                    | 1    |
| *Chryseobacterium meningosepticum* | 1           | 0                    | 0    |
| *Chryseobacterium indoligenes*  | 1              | 0                    | 1    |
| *Proteus mirabilis*             | 1              | 0                    | 0    |
| *Acinetobacter baumanii*        | 1              | 0                    | 1    |
| *Citrobacter freundii*          | 1              | 0                    | 1    |
| *Stenotrophomonas maltophilia*  | 1              | 0                    | 0    |
| *Acinetobacter lwoffi*          | 1              | 0                    | 0    |
| *Edwardsiella tarda*            | 1              | 0                    | 0    |
| *Burkholderia cepacia*          | 1              | 0                    | 0    |
| CRE = carbopenem-resistant enterobacteriaceae; MDR = multiple drug resistance.

**DISCUSSION**

Up to 30% of neutropenic fever in cancer patients are associated with confirmed bacteremia.8,14–16 A large amount of prior clinical studies revealed that the etiological agents in neutropenic patients with BSI were commonly GPB followed by GNB and then fungi.1 In an analysis of bacteremia from 2 pooled European cohorts of 2142 patients with neutropenic fever between October 1994 and February 2005, gram-positive bacteremia had a frequency of 57% with 34% gram-negative bacteremias and 10% polymicrobial bacteremias.4 To the contrary, in a large-scale surveillance study including 7058 patients with hematologic disease at National Taiwan University Hospital...
FIGURE 1. (A) The BSI-related mortality after documentation of BSI. (B) The 90-d overall survival of 85 patients who had BSI during the neutropenia. BSI = bloodstream infection.

FIGURE 2. (A) Comparison of BSI-related mortality in patients receiving autologous HSCT (0) and allogeneic HSCT (17.8 ± 4.9%, \( P = 0.04 \)). (B) Comparison of BSI-related mortality in patients undergoing HSCT with standard-risk (22.6 ± 6.6%) and high-risk disease (4.5 ± 3.1%, \( P = 0.014 \)). (C) Comparison of BSI-related mortality in patients with carbapenem-resistant gram-negative bacteria infection (70.0 ± 14.5%) and non-CRE infection (5.4 ± 2.6%, \( P < 0.001 \)). (D) Comparison of BSI-related mortality in patients with neutropenia <15 d CRE (1.7 ± 1.7%) and prolonged neutropenia (≥15 d, 38.5 ± 9.5%, \( P < 0.001 \)). BSI = bloodstream infection; CRE = carbapenem-resistant enterobacteriaceae; HSCT = hematopoietic stem cell transplant.
between 2002 and 2006, a total of 1307 nonduplicate bloodstream isolates were identified from neutropenic patients. GNB predominated (60%) with *E coli* (12%) followed by *K pneumoniae* (10%), *Acinetobacter calcoaceticus–baumannii complex* (6%), and *S maltophilia* (6%) as the most frequent causal bacteria while coagulase-negative *Staphylococci* and *S aureus* were the most common gram-positive pathogens.17

As to the BSIs in patients undergoing HSCT, there was also a significant variation of epidemiology as shown in Table 6. Most European studies demonstrated a predominance of GPB (50–80%),15,16,18–21 while most studies from developing countries such as Asia-Pacific region demonstrated a predominance of GNB (54–67%).22–25 In our series, a constant dominance of gram-negative bacteremia over 7-year period was documented. These data were comparable to the surveillance study from Institute of Hematology, Peking University between January 2008 and October 2010. In their report of 75 BSI, the incidence of GNB, GPB, and fungal were 64.4%, 30.1%, and 5.5%, respectively. The mortality rate was 6.7% (5/75) while only 1 case of carbapenem-resistant GNB was identified.23

There are 2 possible explanations of the predominance of GNB in our study. First, though it is difficult to make confirmed conclusion due to limited data in HSCT patients, the 2 separate reports from China including ours (23) were comparable to the Chinese national surveillance studies of all clinical isolates (CHINET year 2013), which reported an overwhelming predominance of GNB (71.9%) over GPB (28.1%).26 thus reflects the local epidemiology in China which was significantly different from Europe and North American. Secondary, there were clinical reports from various studies show that epidemiological predominance of GNB causing severe infections in neutropenic patients was associated with antibacterial prophylaxis, while the levofloxacin was routinely used in our transplantation program as part of antibiotics prophylaxis.27–29

As to the drug resistance, in our series, the resistant isolates were mostly observed in GNB with more commonly in *E coli* (25%) and *K pneumoniae* (25%) which was compatible to the CHINET study.7 Of note, a relatively high percentage of

### TABLE 5. Analysis of Risk Factors for BSI Mortality

|                      | Nonsurvivor (n = 11) | Survivor (n = 74) | Univariate P Value | Multivariate P Value | Relative Risk (95% CI) |
|----------------------|----------------------|-------------------|--------------------|----------------------|------------------------|
| Age, yr              |                      |                   | 0.45               | /                    | /                      |
| ≤35                  | 5                    | 46                |                    |                      | /                      |
| >35                  | 6                    | 28                |                    |                      | /                      |
| Gender               |                      |                   | 0.29               | /                    | /                      |
| Male                 | 7                    | 39                |                    |                      | /                      |
| Female               | 4                    | 35                |                    |                      | /                      |
| Type of BSI          |                      |                   | 0.053              | 0.69                 | /                      |
| Polymicrobial and/or secondary BSI | 4 10 |                  |                    |                      | /                      |
| Non                  | 7                    | 64                |                    |                      | /                      |
| Disease status       |                      |                   | 0.014              | 0.031                | 4.4 (1.306–20.800)     |
| Standard risk        | 2                    | 49                |                    |                      | /                      |
| High risk            | 9                    | 25                |                    |                      | /                      |
| HSCT type            |                      |                   | 0.039              | 0.18                 | /                      |
| Autologous           | 0                    | 22                |                    |                      | /                      |
| Allogenic            | 11                   | 52                |                    |                      | /                      |
| Duration of neutropenia |                  |                   | <0.001             | 0.007                | 16.7 (4.81–58.00)      |
| ≤14 d                | 1                    | 58                |                    |                      | /                      |
| ≥15 d                | 10                   | 16                |                    |                      | /                      |
| Drug resistance      |                      |                   | <0.001             | 0.041                | 4.4 (1.14–17.28)       |
| Non-MDR isolates     | 4                    | 55                |                    |                      | /                      |
| Other MDR isolates   | 0                    | 14                |                    |                      | /                      |
| Carbopenem-resistant MDR | 7 5 |                  |                    |                      | /                      |

BSI = bloodstream infection; CI = confidence interval; HSCT = hematopoietic stem cell transplant; MDR = multiple drug resistance.

As to the BSIs in patients undergoing HSCT, there was also a significant variation of epidemiology as shown in Table 6. Most European studies demonstrated a predominance of GPB (50–80%),15,16,18–21 while most studies from developing countries such as Asia-Pacific region demonstrated a predominance of GNB (54–67%).22–25 In our series, a constant dominance of gram-negative bacteremia over 7-year period was documented. These data were comparable to the surveillance study from Institute of Hematology, Peking University between January 2008 and October 2010. In their report of 75 BSI, the incidence of GNB, GPB, and fungal were 64.4%, 30.1%, and 5.5%, respectively. The mortality rate was 6.7% (5/75) while only 1 case of carbapenem-resistant GNB was identified.23

There are 2 possible explanations of the predominance of GNB in our study. First, though it is difficult to make confirmed conclusion due to limited data in HSCT patients, the 2 separate reports from China including ours (23) were comparable to the Chinese national surveillance studies of all clinical isolates (CHINET year 2013), which reported an overwhelming predominance of GNB (71.9%) over GPB (28.1%).26 thus reflects the local epidemiology in China which was significantly different from Europe and North American. Secondary, there were clinical reports from various studies show that epidemiological predominance of GNB causing severe infections in neutropenic patients was associated with antibacterial prophylaxis, while the levofloxacin was routinely used in our transplantation program as part of antibiotics prophylaxis.27–29

As to the drug resistance, in our series, the resistant isolates were mostly observed in GNB with more commonly in *E coli* (25%) and *K pneumoniae* (25%) which was compatible to the CHINET study.7 Of note, a relatively high percentage of

FIGURE 3. Comparison of patients with 0 to 1, 2, and 3 risk factors for BSI-related mortality: BSI-related mortality rate were 4.5% ± 1.5%, 41.7 ± 14.2%, and 83.3 ± 15.2%, respectively. BSI = bloodstream infection.
Previous analysis has documented significant correlation between risk factors for BSI-related mortality in HSCT recipients. 

**Table 6: Summary of BSI Study in Patients Undergoing HSCT**

| Study            | No. of BSI | No. of Isolates | GNB | GPB | Fungal | Comments: MDR and Mortality |
|------------------|------------|-----------------|-----|-----|--------|-------------------------------|
| Poutsia et al.15 | 106        | /               | 21% | 68% | 11%    | BSI predictor of mortality (HR 1.79, P = 0.007) particularly in BSI with GNB and VRE |
| Mikulska et al.16| 168        | 181             | 37% | 57% | 6%     | 7- and 30-d mortality 10% and 24% (GNB, 22% and 31% (GNB) |
| Mikulska et al.18| 149        | /               | 33% | 54% | 3%     | Resistance to FQ: 13% (GPB); 50% (GNB), Mortality 1/32 (3%) |
| Busca et al.19   | 30         | 32              | 12  | 53% | 18     | Low attributable mortality of BSI; crude 120-d mortality 21% |
| Blennow et al.20 | 21% in pts | 521             | 13% | 80% | /      | 47% BSI with GNB; 37% with GPB; 16% with both GNB/GPB |
| Castagnola et al.21 | 130     | 143             | 59  | 50% | 9      | Mortality 7/75 (6.7%) |
| Oliveira et al.22| 91         | 118             | 59 (50%) | 79 (50%) | / | 6-mo mortality (P = 0.021) and LOH (P = 0.014), MDR/CRE GNB with levofloxacin prophylaxis |
| Han et al.23     | 75         | /               | 64.4% | 30.1% | 5.5% | 27 (69%) BSI with MDR |
| Liu et al.24     | 61         | 79              | 47 (54%) | 32 (36%) | / | Multiple drug resistance; VRE = vancomycin-resistant enterococci. |
| El-Mahallawy et al.25 | 39   | /               | 26 (67%) | 14 (33%) | / | Low attributable mortality of BSI; crude 120-d mortality 21% |

**TABLE 6. Summary of BSI Study in Patients Undergoing HSCT**

Pediatric patients.

BSI = blood steam infection; CoNS = coagulase-negative *Staphylococcus* spp.; CRE = carbopenem-resistant enterobacteriaeae; *E coli* = *Escherichia coli*; FQ = fluoroquinolones; GNB = gram-negative bacteria; GPB = gram-positive bacteria; HSCT = hematopoietic stem cell transplant; HR = hazards ratio; LOH = length of hospital; MDR = multiple drug resistance; VRE = vancomycin-resistant enterococci.

carbapenem-resistant GNB was documented in our series. A total of 12 isolated out of 76 (15.7%) GNB isolates were MDR and carbapenem resistance. Even the natural resistant *S maltophilia* were excluded, the incidence of MDR and carbapenem resistant remained as high as 30.1% and 12.3%, respectively. This observation was significantly higher than the report from Peking University. More importantly, the BSI with carbapenem-resistant GNB was associated with a higher mortality rate (7/12) compared with all other patients (4/73) including BSI mortality was high in high-risk patients usually with uncontrolled disease compared to those with standard-risk disease at HSCT. Such a difference might be due to the fact that patients with high-risk disease usually have received multiple cycles of intensive chemotherapy, resulting in more severe immunosuppression, longer hospitalization, higher exposure to antimicrobial treatment and sometimes, the presence of severe infections before HSCT or prolonged pretransplantation neutropenia as previously reported.18 Besides, underlying disease and prolonged neutropenia also played a pivotal role in BSI-related mortality in our study. BSI mortality was high in high-risk patients usually with uncontrolled disease compared to those with standard-risk disease at HSCT. Such a difference might be due to the fact that patients with high-risk disease usually have received multiple cycles of intensive chemotherapy, resulting in more severe immunosuppression, longer hospitalization, higher exposure to antimicrobial treatment and sometimes, the presence of severe infections before HSCT or prolonged pretransplantation neutropenia as previously reported.18

Limitations of the study include its retrospective nature, limited number of patients with BSI, diagnosis, and treatment procedure based on single hospital protocol. Although the data reflect real-life practice in our hospital, these limitations precluded any confirmed conclusion particularly concerning the analysis of risk factors for BSI-related mortality.

Overall, our report revealed a unique epidemiology feature of BSIs in patients undergoing HSCT, which was characterized by predominance of GNB with emerging of MDR/CRE isolates. This may highlight the importance to raise awareness of the local epidemiology data and the drug resistance features to guide the infection control, optimization of empirical antibiotic therapy, and antimicrobial therapy stewardship particularly for those patients undergoing with high-risk diseases, when encountered with prolonged neutropenia.1,12,33

ACKNOWLEDGMENTS

The authors thank Dr Ming Wan and Dr Jun-Cai Xu from Shanghai Clinical Research Center for assistance in the statistics analysis.
REFERENCES

1. Ruhnke M, Arnold R, Gastmeier P. Infection control issues in patients with haematological malignancies in the era of multidrug-resistant bacteria. Lancet Oncol. 2014;15:e606–e619.

2. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:427–431.

3. Wisplinghoff H, Seifert H, Wenzel RP, et al. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis. 2003;36:1103–1110.

4. Klastersky J, Ameye L, Maertens J, et al. Bacteremia in febrile neutropenic cancer patients. Int J Antimicrob Agents. 2007;30(Suppl 1):S51–S59.

5. Gudiol C, Bedro M, Simonetti A, et al. Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients. Clin Microbiol Infect. 2013;19:474–479.

6. Tacconelli E, Cataldo MA, Dancer SJ, et al. ESCMID guidelines for the management of multidrug resistance gram-negative bacteria in hospitalised patients. Clin Microbiol Infect. 2014;20(Suppl 1):1–55.

7. Hu FP, Zhu DM, Wang F, et al. CHINET 2013 surveillance of bacterial resistance in China. Chin J Infect Chemother. 2014;14:369–378.

8. Cappellano P, Viscoli C, Bruzzi P, et al. Epidemiology and risk factors for bloodstream infections after allogeneic hematopoietic stem cell transplantation. New Microbiol. 2007;30:89–99.

9. Frère P, Hermance JP, Debouge MH, et al. Bacteremia after hematopoietic stem cell transplantation: incidence and predictive value of surveillance cultures. Bone Marrow Transplant. 2004;33:745–749.

10. Chen X, Wang WK, Han LZ, et al. Epidemiological and genetic diversity of Staphylococcus aureus causing bloodstream infection in Shanghai. PLoS ONE. 2013;8:e72811.

11. Franklin RC, Matthew AW, Jeff A, et al. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Second Informational Supplement. CLSI Document M100-S22. Wayne, PA: CLSI and the National Committee for Clinical Laboratory Standards; 2012.

12. Averbuch D, Cordonnier C, Livermore DM, et al. Targeted therapy against multi-resistant bacteria in leukaemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukaemia (ECIL-4, 2011). Haematologica. 2013;98:1836–1847.

13. Majgoratos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268–281.

14. Almyroudis NG, Fuller A, Sepkowitz KA, et al. Pre- and post-engraftment bloodstream infection rates and associated mortality in allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2005;7:11–17.

15. Poutsiaka DD, Price LL, Ucuzian A, et al. Blood stream infection after hematopoietic stem cell transplantation is associated with increased mortality. Bone Marrow Transplant. 2007;40:63–70.

16. Mikulska M, Del Bono V, Raiola AM, et al. Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: reemergence of Gram-negative rods and increasing antibiotic resistance. Biol Blood Marrow Transplant. 2009;15:47–53.

17. Chen CY, Tsay W, Tang JL, et al. Epidemiology of bloodstream infections in patients with haematological malignancies with and without neutropenia. Epidemiol Infect. 2010;138:1044–1051.

18. Mikulska M, Del Bono V, Bruzzi P, et al. Mortality after bloodstream infections in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Infection. 2012;40:271–278.

19. Busca A, Cavecchia I, Locatelli F, et al. Blood stream infections after allogeneic stem cell transplantation: a single-center experience with the use of levofloxacin prophylaxis. Transpl Infect Dis. 2012;14:40–48.

20. Blennow O, Ljungman P, Sparrelid E, et al. Incidence, risk factors, and outcome of bloodstream infections during the pre-engraftment phase in 521 allogeneic hematopoietic stem cell transplantations. Transplant Infect Dis. 2014;16:106–114.

21. Castagnola E, Bagnasco F, Faraci M, et al. Incidence of bacteremias and invasive mycoses in children undergoing allogeneic hematopoietic stem cell transplantation: a single center experience. Bone Marrow Transplant. 2008;41:339–347.

22. Oliveira AL, de Souza M, Carvalho-Dias VM, et al. Epidemiology of bacteremia and factors associated with multidrug-resistant gram-negative bacteremia in hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2007;39:775–781.

23. Han TT, Huang XJ, Liu KY, et al. Blood stream infections during agraunulocytosis period after hematopoietic stem cell transplantation in one single center. Zhonghua Nan Ke Zhi. 2011;50:654–658.

24. Liu CY, Lai YC, Huang L, et al. Impact of bloodstream infections on outcome and the influence of prophylactic oral antibiotic regimens in allogeneic hematopoietic SCT recipients. Bone Marrow Transplant. 2011;46:1231–1239.

25. El-Mahallawy H, Samir I, Abdel Fattah R, et al. Source, pattern and antibiotic resistance of blood stream infections in hematopoietic stem cell transplant recipients. J Egypt Natl Cancer Inst. 2014;26:73–77.

26. Wang F, Zhu DM, Hu FP, et al. 2012 CHINET surveillance of bacterial resistance in China. Chin J Infect Chemother. 2013;13:321–330.

27. Cattaneo C, Quaresmini G, Casari S, et al. Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution. J Antimicrob Chemother. 2008;61:721–728.

28. Trecarichi EM, Tumbarello M, Cairi M, et al. Multidrug resistant Pseudomonas aeruginosa bloodstream infection in adult patients with hematologic malignancies. Haematologica. 2011;96:e1–e3.

29. Katsios CM, Burry L, Nelson S, et al. An antimicrobial stewardship program improves antimicrobial treatment by culture site and the value of surveillance cultures. J Antimicrob Chemother. 2012;16:R216.

30. Gupta N, Limbago BM, Patel JB, et al. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis. 2011;53:60–67.

31. Perez F, Van Duin D. Carbapenem-resistant Enterobacteriaceae: a menace to our most vulnerable patients. Cleve Clin J Med. 2013;80:225–233.

32. Scott BL, Park YJ, Deeg HJ, et al. Pretransplant neutropenia is associated with poor-risk cytogenetic features and increased infection-related mortality in patients with myelodysplastic syndromes. Biol Blood Marrow Transplant. 2008;14:799–806.

33. Gyssens IC, Kern WV, Livermore DM. ECIL-4, a joint venture of EBMT, EORTC, ICHS and ESGICH of ESCMID. The role of antibiotic stewardship in limiting antibacterial resistance among hematology patients. Haematologica. 2013;98:1821–1825.